Benefits
Joint comfort and daily activities in one maker-funded trial
In a single 8-week double-blind, placebo-controlled trial in adults with osteoarthritis or rheumatoid arthritis, the group taking 400 mg/day of the maker's freeze-dried olive vegetation water improved significantly on a daily-activities disability score, the main outcome, and the osteoarthritis group improved on a 28-joint pain and inflammation score. CreAgri funded it, and it has not been repeated.
Oxidative stress markers fell with plain hydroxytyrosol, not Hidrox
Not tested as Hidrox. In a single 16-week placebo-controlled trial in 49 adults with overweight and prediabetes, 15 mg/day of hydroxytyrosol, Hidrox's main polyphenol, lowered oxidized LDL (the main outcome), protein carbonyls and a DNA oxidation marker, and kept antioxidant status from falling. Blood lipids did not change.
Blood glutathione rose after one dose of an olive water preparation
In 98 healthy adults, 2 mL of a commercially available olive mill wastewater preparation raised blood glutathione, a natural antioxidant, within 1 hour, while plasma antioxidant capacity did not change. This preliminary study had no placebo group, and the abstract does not name the product; the maker's president co-authored it, but use of Hidrox is unconfirmed.
Homocysteine, a heart health marker, fell in one trial subgroup
In the same single maker-funded 8-week trial, participants with rheumatoid arthritis who took 400 mg/day had a significant fall in blood homocysteine, a marker linked to heart health. It was a subgroup finding, and no other clinical blood marker changed. Heart health outcomes have not been tested with Hidrox.
Inflammation markers: a borderline IL-6 drop with hydroxytyrosol, not Hidrox
Not tested as Hidrox. In a single 16-week trial in 49 adults with overweight and prediabetes, 15 mg/day of hydroxytyrosol lowered IL-6 versus placebo at borderline significance (p = 0.05), a secondary outcome. In an 11-day trial of a different olive fruit extract giving 50 or 100 mg hydroxytyrosol daily, CRP did not differ from placebo. The evidence is preliminary.
EU olive polyphenol claim covers olive oil, not this powder
The EU allows the claim that olive oil polyphenols contribute to the protection of blood lipids from oxidative stress only for olive oil with at least 5 mg of hydroxytyrosol and its derivatives per 20 g, with the effect obtained at 20 g of olive oil a day. It is not an authorised claim for supplements such as Hidrox, whatever their hydroxytyrosol content.
What Hidrox is: a hydroxytyrosol-rich olive water powder
Hidrox is a hydrolyzed, freeze-dried extract of olive vegetation water, the watery juice left after olives are milled for oil. Papers using the 12% grade describe about 12% olive polyphenols, of which hydroxytyrosol is about 40%, or roughly 5% of the powder. Hydroxytyrosol content differs between grades, so check the label.
Mechanism of action
Free-radical scavenging by hydroxytyrosol
Hydroxytyrosol has a catechol group, two neighbouring hydroxyl groups on its ring, that lets it neutralize free radicals in laboratory tests, where it ranks among the most effective food phenols. Test-tube antioxidant strength does not by itself show an antioxidant effect in the body.
Nrf2 antioxidant pathway (animal evidence)
In mice given a chemotherapy drug that damages the testes, oral Hidrox at 50 mg/kg supported the body's own antioxidant defenses through the NRF2 pathway and limited oxidative damage. Nrf2 activation has not been measured in people taking Hidrox.
Inflammatory signalling (animal and cell studies)
In mice given a bacterial toxin, the maker's hydrolyzed olive vegetation water at 500 mg/kg cut blood TNF-alpha, an inflammatory messenger, by 95%, and it halved TNF-alpha release from human immune cells in culture. These doses are far above supplement intakes.
Absorption: rapid, mostly as conjugates
After virgin olive oil, hydroxytyrosol and its methylated metabolite peak in blood within about 30 to 55 minutes, with a half-life of about 2.4 hours, and about 98% circulates and is excreted in conjugated forms. Absorption from Hidrox itself has not been measured in a published human study.
Clinical trials
Double-blind, randomized, placebo-controlled trial run with Arizona State University. The treatment group took 400 mg/day of CreAgri's freeze-dried olive vegetation water, which later Hidrox papers cite as Hidrox research, for 8 weeks; the abstract does not give its hydroxytyrosol content. The main outcome was the HAQ-DI daily-activities disability score. CreAgri funded the study and its president was an author. Not PubMed-indexed. (Bitler et al. 2007, Nutrition Research)
Adults with a diagnosis of osteoarthritis or rheumatoid arthritis.
The treatment group improved significantly on the HAQ-DI, and the osteoarthritis subgroup on the extract improved on the 28-joint disease activity score (DAS28). Blood homocysteine fell significantly in the rheumatoid arthritis subgroup. No other clinical marker changed, including kidney and liver function markers. The trial has not been repeated.
Uncontrolled before-and-after study: blood was drawn after an overnight fast and 1 hour after 2 mL of a commercially available olive mill wastewater preparation. The abstract does not name the product; CreAgri's president was a co-author, but use of Hidrox is not confirmed, so it is not counted as a Hidrox trial. (Visioli et al. 2009, Journal of Agricultural and Food Chemistry)
98 healthy adults of normal body weight.
Total plasma glutathione rose 1 hour after the dose, in both its reduced and oxidized forms, so their ratio did not change. Plasma antioxidant capacity did not change. There was no placebo or control drink.
Randomized, double-blind, placebo-controlled parallel trial (NCT06295913) in Spain. Participants took 15 mg/day of hydroxytyrosol or placebo for 16 weeks; the abstract does not name the supplier, so this is class evidence for hydroxytyrosol, not a Hidrox trial. Oxidized LDL was the primary outcome. The authors declare no conflicts. (Moratilla-Rivera et al. 2025, Clinical Nutrition)
52 adults aged 40 to 70 with overweight and prediabetes randomized; 49 completed.
Compared with placebo, hydroxytyrosol lowered oxidized LDL (p = 0.045), protein carbonyls and the DNA oxidation marker 8-OHdG, prevented a fall in total antioxidant status and GPx activity, and lowered IL-6 at borderline significance (p = 0.05). Blood lipids, body measurements and lifestyle measures did not change, and no adverse events occurred.
Double-blind, placebo-controlled study of a proprietary standardized olive fruit extract (SOFE) at 250 or 500 mg/day, giving 50 or 100 mg of hydroxytyrosol, versus placebo for 11 days. It is a different olive product, so this is class evidence. Euromed, which employed all three authors, funded the study. (Pais et al. 2016, Drugs in R&D)
36 subjects at risk of arterial stiffness, 12 per group.
All three groups, including placebo, had lower CAVI arterial stiffness scores, with no significant difference between groups. CRP did not differ significantly between groups. In the full text, mean triglycerides in the 500 mg group fell 21.64% (p = 0.03 versus placebo), an exploratory endpoint, from a higher starting level than the placebo group's.
Pharmacokinetic study: plasma and urine were collected for 12 hours after 25 mL of virgin olive oil, and hydroxytyrosol and 3-O-methyl-hydroxytyrosol were measured. It tested olive oil, not Hidrox, and had no health outcome. (Miro-Casas et al. 2003, Clinical Chemistry)
Volunteers given 25 mL of virgin olive oil; the abstract does not state their number.
Plasma hydroxytyrosol and 3-O-methyl-hydroxytyrosol peaked at 32 and 53 minutes, with a half-life of 2.43 hours. About 98% of hydroxytyrosol appeared in plasma and urine as conjugates, mainly glucuronides, pointing to extensive first-pass metabolism.